<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885712</url>
  </required_header>
  <id_info>
    <org_study_id>BR-DPC-CT-301</org_study_id>
    <nct_id>NCT04885712</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or Pioglitazone 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the&#xD;
      Efficacy and Safety of Pioglitazone 15mg or Pioglitazone 30mg Add-on in Patients with Type 2&#xD;
      Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in HbA1c</measure>
    <time_frame>24th week</time_frame>
    <description>Changes in HbA1c at the 24th week after the administration of investigational products from the baseline</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">369</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg Pioglitazone 30mg placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 30mg Pioglitazone 15mg placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg placebo Pioglitazone 30mg placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin≥1000mg</intervention_name>
    <description>Subjects take the investigational products once a day for 24 weeks.</description>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo</arm_group_label>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo</arm_group_label>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo</arm_group_label>
    <other_name>BR3003D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 15mg</intervention_name>
    <description>Subjects take the investigational products once a day for 24 weeks.</description>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo</arm_group_label>
    <other_name>BR3003A-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 30 mg</intervention_name>
    <description>Subjects take the investigational products once a day for 24 weeks.</description>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo</arm_group_label>
    <other_name>BR3003B-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 15mg Placebo</intervention_name>
    <description>Subjects take the investigational products once a day for 24 weeks.</description>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo</arm_group_label>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo</arm_group_label>
    <other_name>BR3003A-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 30mg Placebo</intervention_name>
    <description>Subjects take the investigational products once a day for 24 weeks.</description>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo</arm_group_label>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo</arm_group_label>
    <other_name>BR3003B-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Subjects take the investigational products once a day for 24 weeks.</description>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo</arm_group_label>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo</arm_group_label>
    <arm_group_label>Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo</arm_group_label>
    <other_name>BR3003C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Those who voluntarily signed the informed consent to participate in this study.&#xD;
&#xD;
          2. Adults aged 19 years or older.&#xD;
&#xD;
          3. Those diagnosed with type 2 diabetes mellitus.&#xD;
&#xD;
          4. Subjects taking constant doses of ≥1000mg of Metformin and 10 mg of Dapagliflozin for&#xD;
             more than 8 weeks at Visit 1 (regardless of dosage forms (immediate-release and&#xD;
             sustained-release) and single agent or combination drug.)&#xD;
&#xD;
          5. Subjects with 7% ≤ HbA1c ≤ 10.5% at Visit 1 and Visit 2&#xD;
&#xD;
          6. Subjects able to understand the study, comply with study procedures, and attend all&#xD;
             scheduled visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled hyperglycemia at Visit 1 or Visit 2 (subjects with FPG &gt; 270 mg/dL as a&#xD;
             result of the test conducted by the study institution.)&#xD;
&#xD;
          2. Medication compliance is &lt;70% or &gt;120% for each BR3003D, BR3003C, BR3003A-2, and&#xD;
             BR3003B-2 during the Run-in period at Visit 2.&#xD;
&#xD;
          3. Patients with other types of diabetes instead of type 2 diabetes (e.g., type 1&#xD;
             diabetes, secondary diabetes, or congenital renal glycosuria).&#xD;
&#xD;
          4. Patients with uncontrolled, severe diabetic complications (e.g., proliferative&#xD;
             diabetic retinopathy uncontrolled despite medication and severe diabetic neuropathy)&#xD;
&#xD;
          5. Those who suffered from acute or chronic metabolic acidosis within 3 months as of&#xD;
             Visit 1, including lactic acidosis and diabetic ketoacidosis.&#xD;
&#xD;
          6. Those with &gt; 40 kg/m2 of BMI measured at Visit 1.&#xD;
&#xD;
          7. Those with uncontrolled hypertension at Visit 1 or Visit 2 (SBP &gt; 180 mmHg or DBP &gt;&#xD;
             110 mmHg).&#xD;
&#xD;
          8. Those diagnosed with cardiovascular diseases (myocardial infarction, stroke, unstable&#xD;
             angina, and transient ischemic attack (TIA)) or undergo revascularization within 3&#xD;
             months as of Visit 1&#xD;
&#xD;
          9. Those with heart failure (NYHA class II~IV) or who had suffered from heart failure.&#xD;
&#xD;
         10. Those who suffered from gastrointestinal diseases that may affect the absorption,&#xD;
             distribution, metabolism, and excretion of investigational products or had underwent&#xD;
             surgery;&#xD;
&#xD;
         11. Those who underwent surgery requiring general anesthesia within 4 weeks as of Visit 1&#xD;
             or who are scheduled to receive such surgery within 4 weeks after the study ends&#xD;
&#xD;
         12. Those with a history of malignant tumor within 5 years as of Visit 1&#xD;
&#xD;
         13. Those who have a clinically significant liver disease&#xD;
&#xD;
         14. Those who have a clinically significant renal disease&#xD;
&#xD;
         15. Those with clinically significant hematuria detected at Visit 1 or Visit 2&#xD;
&#xD;
         16. Those with chronic diseases requiring the continued use of systemic steroid or&#xD;
             immunosuppressants (oral administration, injection, or inhalation).&#xD;
&#xD;
         17. Patients with pituitary insufficiency or adrenal insufficiency.&#xD;
&#xD;
         18. Those with clinically significant severe infection or trauma based on an&#xD;
             investigator's judgement.&#xD;
&#xD;
         19. Patients with AIDS.&#xD;
&#xD;
         20. Patients with acute or chronic diseases that may cause histotoxic hypoxia such as&#xD;
             respiratory failure and shock.&#xD;
&#xD;
         21. Those who need treatment due to dehydration caused by persistent diarrhea and vomiting&#xD;
             or at a risk of fluid volume depletion.&#xD;
&#xD;
         22. Those who have been administered with the following drugs or expected to require the&#xD;
             continued administration during the study period:&#xD;
&#xD;
               -  Those administered with systemic steroid agents (Prednisolone, &gt;30 mg/day) within&#xD;
                  2 weeks as of Visit 1.&#xD;
&#xD;
               -  Those being administered with thyroid medications and whose dose has been&#xD;
                  modified within 6 weeks as of Visit 1 (however, dose reduction is accepted.)&#xD;
&#xD;
               -  Those being administered with diuretics and whose dose has been modified within 8&#xD;
                  weeks as of Visit 1 however, dose reduction is accepted.)&#xD;
&#xD;
               -  Those who have been administered with antidiabetics other than Metformin and&#xD;
                  Dapagliflozin within 8 weeks as of Visit 1.&#xD;
&#xD;
               -  Those who have been administered with obesity drugs (e.g., phentermine,&#xD;
                  phendimetrazine, diethylpropion, and mazindol) within 12 weeks as of Visit 1.&#xD;
&#xD;
               -  Those who need to take prohibited concomitant medications stated here during the&#xD;
                  study period.&#xD;
&#xD;
         23. Those with history of alcohol or drug abuse within 1 year as of Visit 1.&#xD;
&#xD;
         24. Those who had allergic reaction to main ingredients or components of the&#xD;
             investigational products.&#xD;
&#xD;
         25. Those who had genetic disorders such as galactose intolerance, Lapp lactose&#xD;
             deficiency, or glucose-galactose malabsorption.&#xD;
&#xD;
         26. Females who are pregnant or breastfeeding.&#xD;
&#xD;
         27. Patients planning to become pregnant or of childbearing potential, but not using any&#xD;
             recognized contraceptive method&#xD;
&#xD;
         28. Those who are currently participating in other ongoing clinical studies or those who&#xD;
             have taken the investigational products from other clinical studies within 12 weeks as&#xD;
             of Visit 1&#xD;
&#xD;
         29. Those who are judged unsuitable for the study by a principal investigator or&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo-je Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suhee Kim</last_name>
    <phone>82-2-740-4231</phone>
    <email>shkim0127@boryung.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woo-je Lee</last_name>
      <phone>82-2-3010-5882</phone>
      <email>lwjatlas@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

